On February 7, 2025, Hemispherx BioPharma, operating under AIM ImmunoTech Inc., made public its intentions to conduct a follow-up clinical study to assess a combined treatment approach for avian influenza outbreaks. The study will involve AIM’s Ampligen® along with AstraZeneca’s FluMist®. A detailed press release outlining this initiative has been included in the recent Form 8-K filing as Exhibit 99.1.
The proposed clinical trial follows previous research conducted by AIM at the University of Alabama-Birmingham, where findings suggested that administering Ampligen as an intranasal adjuvant significantly boosted immune responses. This included generating cross-protection through avian influenza antibody production in humans.
CEO of AIM ImmunoTech Inc., Thomas K. Equels, expressed optimism about the potential of this combined therapy to address the growing threat of avian flu outbreaks. The company believes that leveraging Ampligen along with existing vaccines could broaden the spectrum of protection, particularly against avian influenza strains.
The decision to move forward with this clinical study is underpinned by a series of preclinical and clinical experiments that demonstrated the effectiveness of Ampligen in enhancing immunity against various influenza strains. These studies showed promising results, reinforcing the company’s confidence in the potential efficacy of such combination therapies.
The overarching objective of Hemispherx BioPharma’s research and development efforts is centered around advancing novel treatments for a range of viral diseases, immune disorders, and cancers, including the ongoing focus on COVID-19. Ampligen® (rintatolimod) stands as the company’s lead product, showing promise as an immuno-modulator with broad-spectrum activity in clinical trials.
Investors are advised to approach forward-looking statements included in this disclosure with caution, acknowledging the inherent risks and uncertainties associated with such endeavors. Hemispherx BioPharma stresses the importance of considering the risk factors outlined in its regulatory filings.
For further details and updates, investors can visit the company’s official website at aimimmuno.com and follow its developments on various social media platforms.
This press release shall not be considered as financial advice or a recommendation for investment decisions but rather as information for the general public and investors to keep abreast of the company’s activities in the biomedical research sphere.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Hemispherx BioPharma’s 8K filing here.
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Further Reading
- Five stocks we like better than Hemispherx BioPharma
- 3 Monster Growth Stocks to Buy Now
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
- Want to Profit on the Downtrend? Downtrends, Explained.
- High-Momentum ETFs Leading the Market This Year
- 3 Warren Buffett Stocks to Buy Now
- How Alibaba Stock Could Defy Trade Tariffs and Surge Higher
